RA CAPITAL MANAGEMENT, L.P.
CIK: 0001346824Latest portfolio: $9.8B · Q4 2025
Holdings
71
Total Value
$9.8B
New Positions
22
Closed Positions
18
Top Holdings
View All 71 Holdings →| # | Stock | Shares | Value | % Portfolio | Change | Type |
|---|---|---|---|---|---|---|
| 1 | ASNDASCENDIS PHARMA A/S - ADR | 10,281,496 | $2.2B | 22.46% | — | |
| 2 | CDTXCIDARA THERAPEUTICS INC | 3,365,523 | $743.4M | 7.62% | — | |
| 3 | RYTMRHYTHM PHARMACEUTICALS INC | 6,666,837 | $713.6M | 7.31% | +985K | |
| 4 | RNAAVIDITY BIOSCIENCES INC | 8,641,031 | $623.3M | 6.39% | — | |
| 5 | PCVXVAXCYTE INC | 10,724,599 | $494.8M | 5.07% | -1,241,392 | |
| 6 | SIONSIONNA THERAPEUTICS INC | 9,905,045 | $407.5M | 4.17% | -540,277 | |
| 7 | NAMSNEWAMSTERDAM PHARMA CO NV | 9,550,191 | $335.0M | 3.43% | -588,747 | |
| 8 | TYRATYRA BIOSCIENCES INC | 12,198,625 | $320.7M | 3.29% | — | |
| 9 | WVEWAVE LIFE SCIENCES LTD | 18,203,009 | $309.5M | 3.17% | +1K | |
| 10 | MLYSMINERALYS THERAPEUTICS INC | 7,323,750 | $265.8M | 2.72% | — | |
| 11 | EWTXEDGEWISE THERAPEUTICS INC | 10,428,437 | $258.8M | 2.65% | — | |
| 12 | SEPNSEPTERNA INC | 6,995,858 | $195.0M | 2.00% | — | |
| 13 | NUVLNUVALENT INC-A | 1,880,057 | $189.1M | 1.94% | +634K | |
| 14 | IRONDISC MEDICINE INC | 1,976,132 | $156.9M | 1.61% | +399K | |
| 15 | JANXJANUX THERAPEUTICS INC | 11,189,693 | $154.4M | 1.58% | — | |
| 16 | PEPGPEPGEN INC | 20,064,545 | $130.6M | 1.34% | — | |
| 17 | TSHATAYSHA GENE THERAPIES INC | 23,555,648 | $129.6M | 1.33% | — | |
| 18 | SPRYARS PHARMACEUTICALS INC | 10,860,977 | $126.5M | 1.30% | — | |
| 19 | BCRXBIOCRYST PHARMACEUTICALS INC | 15,827,186 | $123.5M | 1.26% | NEW | |
| 20 | BCAXBICARA THERAPEUTICS INC | 6,955,993 | $117.1M | 1.20% | — | |
| 21 | PRAXPRAXIS PRECISION MEDICINES I | 373,787 | $110.2M | 1.13% | NEW | |
| 22 | GHRSGH RESEARCH PLC | 7,676,697 | $97.5M | 1.00% | — | |
| 23 | GONGERON CORP | 63,771,366 | $84.2M | 0.86% | +3.4M | |
| 24 | ACLXARCELLX INC | 1,267,156 | $82.6M | 0.85% | -1,769,371 | |
| 25 | CLYMCLIMB BIO INC | 11,293,828 | $77.7M | 0.80% | -20,125,439 |
Quarterly Changes
New Positions
Sector Breakdown
HealthcareNaN% ($InfinityT)
Unknown0.0% ($743410.8T)
Technology0.0% ($4.7M)
Filing History
| Quarter | Filing Date | Portfolio Value | Holdings |
|---|---|---|---|
| Q4 2025 | Feb 17, 2026 | $9.8B | 72 |
| Q3 2025 | Nov 14, 2025 | $8.1T | 68 |
| Q2 2025 | Aug 14, 2025 | $5.9T | 64 |
| Q1 2025 | May 15, 2025 | $6.0T | 86 |
| Q4 2024 | Feb 14, 2025 | $7.5T | 90 |
| Q3 2024 | Nov 14, 2024 | $8673.6T | 82 |
| Q2 2024 | Aug 14, 2024 | $7560.8T | 79 |
| Q1 2024 | May 15, 2024 | $7798.8T | 75 |
| Q4 2023 | Feb 14, 2024 | $6402.5T | 62 |
| Q3 2023 | Nov 14, 2023 | $5042.1T | 65 |
| Q2 2023 | Aug 14, 2023 | $5296.5T | 54 |
| Q1 2023 | May 15, 2023 | $4417.4T | 59 |
| Q4 2022 | Feb 14, 2023 | $4930.7T | 70 |
| Q3 2022 | Nov 14, 2022 | $4.7T | 81 |
| Q2 2022 | Aug 15, 2022 | $3.8T | 88 |
| Q1 2022 | May 16, 2022 | $4.6T | 96 |
| Q4 2021 | Feb 14, 2022 | $5.7T | 97 |
| Q3 2021 | Nov 15, 2021 | $7.2T | 95 |
| Q2 2021 | Aug 16, 2021 | $6.2T | 92 |
| Q1 2021 | May 17, 2021 | $6.6T | 82 |
| Q4 2020 | Feb 16, 2021 | $7.2T | 82 |
| Q3 2020 | Nov 16, 2020 | $5.5T | 70 |
| Q2 2020 | Aug 14, 2020 | $5.1T | 57 |
| Q1 2020 | May 15, 2020 | $3.2T | 48 |
| Q4 2019 | Feb 14, 2020 | $3.3T | 34 |
| Q3 2019 | Nov 14, 2019 | $1.7T | 32 |
| Q2 2019 | Aug 14, 2019 | $1.9T | 25 |
| Q1 2019 | May 15, 2019 | $2.3T | 29 |
| Q4 2018 | Feb 14, 2019 | $1.7T | 25 |
| Q3 2018 | Nov 14, 2018 | $1.9T | 26 |
| Q2 2018 | Aug 14, 2018 | $1.5T | 27 |
| Q1 2018 | May 15, 2018 | $1.3T | 31 |
| Q4 2017 | Feb 14, 2018 | $1.2T | 27 |
| Q3 2017 | Nov 14, 2017 | $1.1T | 27 |
| Q2 2017 | Aug 14, 2017 | $871.4B | 22 |
| Q1 2017 | May 15, 2017 | $815.3B | 24 |
| Q4 2016 | Feb 14, 2017 | $684.7B | 26 |
| Q3 2016 | Nov 14, 2016 | $969.4B | 31 |
| Q2 2016 | Aug 15, 2016 | $722.2B | 32 |
| Q1 2016 | May 16, 2016 | $782.3B | 42 |
Fund Information
RA CAPITAL MANAGEMENT, L.P. is an institutional investment manager that files 13F reports with the SEC. As of the Q4 2025 filing, the fund reported a portfolio valued at $9.8B across 71 holdings. The largest position is ASCENDIS PHARMA A/S - ADR (ASND), representing 22.5% of the portfolio. Compared to the previous quarter, the fund opened 22 new positions and closed 18 positions. 13F filings are required quarterly disclosures that provide transparency into the holdings of institutional investment managers with at least $100 million in qualifying assets.